There is growing evidence that plant and animal species are arranged in hierarchies of relative competitive performance. More work is needed to determine which plant traits best predict relative competitive performance. We therefore measured relative competitive performance of 63 terrestrial herbaceous plant species using Trichostema brachiatum as a reference species (that is, phytometer or target species). The neighbour species came from a wide array of terrestrial vegetation types (e.g. rock barrens, alvars, old fields), and represented a wide array of growth forms (e.g. small rosette species such as Saxifraga virginiensis and large clonal graminoids such as Agropyron repens). The experiment was repeated with two pot sizes: large (control) and small (stress treatment). Relative competitive performance in large pots (controls) was highly correlated with that in small pots (stress treatment) (r = 0.90, p < 0.001). The hierarchy of relative competitive performance in the large pots was also highly correlated with the hierarchy in the small (stressed) pots (r s = 0.91, p < 0.001). Principal components analysis and multiple linear regression showed that plant size (measured by total biomass, above-ground biomass, below-ground biomass, canopy area, height and leaf area index) and leaf shape (measured as length to width ratio, length, width) were the two characteristics that best predicted relative competitive performance (large pots, r 2 = 0.55; small pots, r 2 = 0.48).

No abstract

Serological SARS-CoV-2 assays are needed to support clinical diagnosis and epidemiological investigations. Recently, assays for large-scale detection of total antibodies (total-Ab) and immunoglobulin (Ig) G and M against SARS-CoV-2 antigens have been developed, but there are limited data on the diagnostic accuracy of these assays. This study was a Danish national collaboration and evaluated fifteen commercial and one in-house anti-SARS-CoV-2 assays in sixteen laboratories. Sensitivity was evaluated using 150 samples from individuals with asymptomatic, mild or moderate COVID-19; nonhospitalized or hospitalized, confirmed by nucleic acid amplification tests (NAAT), collected 13-73 days either from symptom onset or from positive NAAT (patients without symptoms). Specificity and cross reactivity were evaluated in samples collected prior to the SARS-CoV-2 epidemic from >586 blood donors and patients with autoimmune diseases, cytomegalovirus or Epstein-Barr virus infections and acute viral infections. A specificity of ≥99% was achieved by all total-Ab and IgG assays except one, Diasorin/LiaisonXL-IgG (97.2%). Sensitivities in descending order were: Wantai/ELISA total-Ab (96.7%), CUH-NOVO/in-house ELISA total-Ab (96.0%), Ortho/Vitros total-Ab (95.3%), YHLO/iFlash-IgG (94.0%), Ortho/Vitros-IgG (93.3%), Siemens/Atellica total-Ab (93.2%), Roche/Elecsys total-Ab (92.7%), Abbott/Architect-IgG (90.0%), Abbott/Alinity-IgG (median 88.0%), Diasorin/LiaisonXL-IgG (median 84.6%), Siemens/Vista total-Ab (81.0%), Euroimmun/ELISA-IgG (78.0%), and Snibe/Maglumi-IgG (median 78.0%). However, confidence intervals overlapped for several assays. The IgM results were variable, with the Wantai/ELISA-IgM showing the highest sensitivity (82.7%) and specificity (99%). The rate of seropositivity increased with time from symptom onset and symptom severity.

In this study, we report a novel real time polymerase chain reaction (Q‐PCR) method using TaqMan probes for human neutrophil antigens (HNA)‐1, ‐3, ‐4, and ‐5 genotyping. The method was validated in a Caucasian Danish population, a Zambian population, and in clinical samples using three different methods: an in‐house polymerase chain reaction with sequence‐specific primers (PCR‐SSP) method, a commercial available PCR‐SSP kit and a novel Q‐PCR method. We observed no discrepancy in the genotype frequencies determined by the PCR‐SSP methods and the TaqMan assay in the populations studied. In tests of a family of Nigerian origin and in samples carrying the rare SLC44A2*1:2 genotype, different results were produced by the commercial PCR‐SSP kit and the real‐time TaqMan assay. The TaqMan‐based genotyping method was rapid and reproducible, allowing high‐throughput HNA‐1, ‐3, ‐4, and ‐5 genotyping.